• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print

Announcements


MSB Change in substantial holding07/08/20 download Created with Sketch. 85.81KB
MSB Appendix 2A06/08/20 download Created with Sketch. 163.17KB
MSB Proposed issue of Securities - MSB06/08/20 download Created with Sketch. 24.9KB
MSB COVID-19/GVHD Update, Quarterly Report and Appendix 4CPRICE SENSITIVE30/07/20 download Created with Sketch. 230.46KB
MSB Mesoblast Expands Executive Leadership Team24/07/20 download Created with Sketch. 131.59KB
MSB FDA Advisory Committee Sets Review Date for Remestemcel-LPRICE SENSITIVE21/07/20 download Created with Sketch. 108.87KB
MSB Appendix 3B, 2A with prospectus- Kentgrove Capital07/07/20 download Created with Sketch. 809.43KB
MSB EAP for Remestemcel-L in Children with MIS-C due to COVID-1906/07/20 download Created with Sketch. 108.82KB
MSB Appendix 2A30/06/20 download Created with Sketch. 163.22KB
MSB Appendix 3G with 3Ys24/06/20 download Created with Sketch. 267.14KB
MSB Appendix 2A16/06/20 download Created with Sketch. 166.58KB
MSB S&P DJI Announces June 2020 Quarterly RebalancePRICE SENSITIVE12/06/20 download Created with Sketch. 223.16KB
MSB Appendix 2A01/06/20 download Created with Sketch. 164.04KB
MSB Remestemcel-L Improves Outcomes in Inflammatory Lung DiseasePRICE SENSITIVE01/06/20 download Created with Sketch. 116.33KB
MSB MSB Reports Q3 Financial Results and Operational HighlightsPRICE SENSITIVE28/05/20 download Created with Sketch. 281.8KB
MSB Third Quarter Results Presentation28/05/20 download Created with Sketch. 1.72MB
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE28/05/20 download Created with Sketch. 614.49KB
MSB Change in substantial holding27/05/20 download Created with Sketch. 250.69KB
MSB 3 Articles on RYONCIL GvHD Trial Results Published in BBMT25/05/20 download Created with Sketch. 124.22KB
MSB Change in substantial holding19/05/20 download Created with Sketch. 159.15KB
MSB Cleansing Notice18/05/20 download Created with Sketch. 72.61KB
MSB Appendix 2As15/05/20 download Created with Sketch. 375.44KB
MSB Proposed issue of Securities - MSB13/05/20 download Created with Sketch. 27.78KB
MSB MSB Completes Financing For Covid-19 ARDS ManufacturingPRICE SENSITIVE13/05/20 download Created with Sketch. 144.68KB
MSB Trading HaltPRICE SENSITIVE11/05/20 download Created with Sketch. 170.3KB
MSB First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS06/05/20 download Created with Sketch. 128.22KB
MSB Phase 2/3 Trial in COVID-19 ARDS Begins EnrollmentPRICE SENSITIVE30/04/20 download Created with Sketch. 140.07KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE29/04/20 download Created with Sketch. 193.38KB
MSB 83% Survival in COVID-19 ARDS Patients with Remestemcel-LPRICE SENSITIVE24/04/20 download Created with Sketch. 144.87KB
MSB Inflammatory Lung Disease Outcomes For Presentation at ISCT17/04/20 download Created with Sketch. 116.14KB
MSB US NIH Trials Network to Conduct COVID-19 Phase 2/3 TrialPRICE SENSITIVE09/04/20 download Created with Sketch. 95.91KB
MSB FDA Clears IND for Remestemcel Use in COVID-19 ARDS PatientsPRICE SENSITIVE06/04/20 download Created with Sketch. 89.95KB
MSB FDA Accepts BLA for RYONCIL and Agrees to Priority ReviewPRICE SENSITIVE01/04/20 download Created with Sketch. 92.3KB
MSB Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting30/03/20 download Created with Sketch. 94.18KB
MSB Change of Director's Interest Notice20/03/20 download Created with Sketch. 71.77KB
MSB Appendix 2A17/03/20 download Created with Sketch. 147.18KB
MSB Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung DiseasePRICE SENSITIVE10/03/20 download Created with Sketch. 98.41KB
MSB Mesoblast Provides Half Year Results and Corporate UpdatePRICE SENSITIVE27/02/20 download Created with Sketch. 223.76KB
MSB Half Year Financial Results Presentation27/02/20 download Created with Sketch. 1.46MB
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE27/02/20 download Created with Sketch. 757.72KB
MSB Mesoblast Half Year FY 2020 Financial Results Analyst Call25/02/20 download Created with Sketch. 70.25KB
MSB Ryoncil Results in Children with Acute GvHD Presented at TCT24/02/20 download Created with Sketch. 146.94KB
MSB Appendix 3G21/02/20 download Created with Sketch. 131.61KB
MSB Positive Outcomes Using Remestemcel-L in Chronic GVHD20/02/20 download Created with Sketch. 94.61KB
MSB Appendix 2A07/02/20 download Created with Sketch. 165.97KB
MSB Mesoblast Submits Completed BLA for Ryoncil to US FDAPRICE SENSITIVE03/02/20 download Created with Sketch. 114.77KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE29/01/20 download Created with Sketch. 219.65KB
MSB Appendix 2A24/01/20 download Created with Sketch. 147.69KB
MSB Biotech Showcase Presentation15/01/20 download Created with Sketch. 2.05MB
MSB MSB Presents Commercial Plans at 2020 Biotech Showcase15/01/20 download Created with Sketch. 144.16KB
MSB Appendix 2A02/01/20 download Created with Sketch. 143.67KB
MSB MSB Files GvHD Clinical Efficacy and Safety Data with US FDAPRICE SENSITIVE02/01/20 download Created with Sketch. 128.07KB
MSB DMC Completes Final Review of Phase 3 Heart Failure TrialPRICE SENSITIVE18/12/19 download Created with Sketch. 119.18KB
MSB CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)PRICE SENSITIVE17/12/19 download Created with Sketch. 122.93KB
MSB CHF P3 Trial Accrues Sufficient Primary Endpoint EventsPRICE SENSITIVE17/12/19 download Created with Sketch. 122.57KB
MSB Ceasing to be a substantial holder05/12/19 download Created with Sketch. 212.21KB
MSB Change of Director's Interest Notice05/12/19 download Created with Sketch. 70.89KB
MSB Results of Meeting27/11/19 download Created with Sketch. 183.19KB
MSB Mesoblast Chairman Message to 2019 AGM27/11/19 download Created with Sketch. 105.21KB
MSB Presentation to 2019 Annual General Meeting27/11/19 download Created with Sketch. 1.64MB
MSB MSB Provides Q1 Financial Results and Operational HighlightsPRICE SENSITIVE26/11/19 download Created with Sketch. 309.78KB
MSB First Quarter Results Presentation26/11/19 download Created with Sketch. 1.67MB
MSB First Quarter Financial Results on Form 6-KPRICE SENSITIVE26/11/19 download Created with Sketch. 502.82KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/19 download Created with Sketch. 212.78KB
MSB Annual Report to shareholders29/10/19 download Created with Sketch. 5.08MB
MSB Notice of General Meeting/Proxy Form29/10/19 download Created with Sketch. 304.7KB
MSB Appendix 4G and Corporate Governance Statement29/10/19 download Created with Sketch. 242KB
MSB Appointment of Joint Company Secretary29/10/19 download Created with Sketch. 92.31KB
MSB Ceasing to be a substantial holder23/10/19 download Created with Sketch. 41.85KB
MSB Change in substantial holding23/10/19 download Created with Sketch. 85.89KB
MSB Change in substantial holding23/10/19 download Created with Sketch. 231.98KB
MSB MSB and Lonza Enter GVHD Commercial Manufacturing AgreementPRICE SENSITIVE17/10/19 download Created with Sketch. 94.01KB
MSB Change in substantial holding10/10/19 download Created with Sketch. 526.49KB
MSB Cleansing notice and Appendix 3B08/10/19 download Created with Sketch. 197.29KB
MSB Change in substantial holding08/10/19 download Created with Sketch. 71.35KB
MSB Mesoblast Raises A$75 MillionPRICE SENSITIVE03/10/19 download Created with Sketch. 112.24KB
MSB Trading HaltPRICE SENSITIVE01/10/19 download Created with Sketch. 288.32KB
MSB Release of Shares from Voluntary Escrow27/09/19 download Created with Sketch. 86.42KB
MSB Mesoblast Newsletter - Chronic Low Back Pain27/09/19 download Created with Sketch. 575.08KB
MSB Analyst Call Presentation10/09/19 download Created with Sketch. 1.7MB
MSB Analyst Call Details10/09/19 download Created with Sketch. 83.18KB
MSB Grunenthal and MSB Enter Strategic Partnership for Back PainPRICE SENSITIVE10/09/19 download Created with Sketch. 127.73KB
MSB Mesoblast Reports on Annual ResultsPRICE SENSITIVE30/08/19 download Created with Sketch. 243.33KB
MSB Annual Financial Results Presentation30/08/19 download Created with Sketch. 4.48MB
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/19 download Created with Sketch. 3.68MB
MSB FDA Guidance on Clinical Pathway for LVAD Market ApplicationPRICE SENSITIVE27/08/19 download Created with Sketch. 108.18KB
MSB Investigator-Initiated Trial Planned for Chronic GVHD14/08/19 download Created with Sketch. 73.45KB
MSB Mesoblast Appoints Leading Pharma Industry Executive as CMO12/08/19 download Created with Sketch. 72.69KB
MSB Appendix 4C - Quarterly, Strong Commercialization RevenuesPRICE SENSITIVE31/07/19 download Created with Sketch. 198.68KB
MSB Circulation Research Highlights MSB Heart Failure TherapyPRICE SENSITIVE25/07/19 download Created with Sketch. 125.8KB
MSB Newsletter - Interview with GvHD Key Opinion Leader15/07/19 download Created with Sketch. 931.81KB
MSB Change in substantial holding12/07/19 download Created with Sketch. 77.12KB
MSB Appendix 3B11/07/19 download Created with Sketch. 113.03KB
MSB Release of Shares from Voluntary Escrow26/06/19 download Created with Sketch. 86.12KB
MSB FDA Grants Revascor Orphan Drug For End Stage CHF With LVADsPRICE SENSITIVE24/06/19 download Created with Sketch. 134.93KB
MSB High Economic Burden In Steroid-Refractory aGVHD18/06/19 download Created with Sketch. 94.6KB
MSB MSB to Host Virtual Symposium with KOL on GvHD17/06/19 download Created with Sketch. 92.26KB
MSB MSB Expands JCR Partnership To Brain Disease In NewbornsPRICE SENSITIVE11/06/19 download Created with Sketch. 94.26KB
MSB MSB Provides Q3 Financial Results and Operational HighlightsPRICE SENSITIVE31/05/19 download Created with Sketch. 184.53KB
MSB Third Quarter Results Presentation31/05/19 download Created with Sketch. 3.41MB
MSB Change in substantial holding
07/08/20 download Created with Sketch. 85.81KB
MSB Appendix 2A
06/08/20 download Created with Sketch. 163.17KB
MSB Proposed issue of Securities - MSB
06/08/20 download Created with Sketch. 24.9KB
MSB COVID-19/GVHD Update, Quarterly Report and Appendix 4C
30/07/20PRICE SENSITIVE download Created with Sketch. 230.46KB
MSB Mesoblast Expands Executive Leadership Team
24/07/20 download Created with Sketch. 131.59KB
MSB FDA Advisory Committee Sets Review Date for Remestemcel-L
21/07/20PRICE SENSITIVE download Created with Sketch. 108.87KB
MSB Appendix 3B, 2A with prospectus- Kentgrove Capital
07/07/20 download Created with Sketch. 809.43KB
MSB EAP for Remestemcel-L in Children with MIS-C due to COVID-19
06/07/20 download Created with Sketch. 108.82KB
MSB Appendix 2A
30/06/20 download Created with Sketch. 163.22KB
MSB Appendix 3G with 3Ys
24/06/20 download Created with Sketch. 267.14KB
MSB Appendix 2A
16/06/20 download Created with Sketch. 166.58KB
MSB S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20PRICE SENSITIVE download Created with Sketch. 223.16KB
MSB Appendix 2A
01/06/20 download Created with Sketch. 164.04KB
MSB Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
01/06/20PRICE SENSITIVE download Created with Sketch. 116.33KB
MSB MSB Reports Q3 Financial Results and Operational Highlights
28/05/20PRICE SENSITIVE download Created with Sketch. 281.8KB
MSB Third Quarter Results Presentation
28/05/20 download Created with Sketch. 1.72MB
MSB Third Quarter Financial Results on Form 6-K
28/05/20PRICE SENSITIVE download Created with Sketch. 614.49KB
MSB Change in substantial holding
27/05/20 download Created with Sketch. 250.69KB
MSB 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
25/05/20 download Created with Sketch. 124.22KB
MSB Change in substantial holding
19/05/20 download Created with Sketch. 159.15KB
MSB Cleansing Notice
18/05/20 download Created with Sketch. 72.61KB
MSB Appendix 2As
15/05/20 download Created with Sketch. 375.44KB
MSB Proposed issue of Securities - MSB
13/05/20 download Created with Sketch. 27.78KB
MSB MSB Completes Financing For Covid-19 ARDS Manufacturing
13/05/20PRICE SENSITIVE download Created with Sketch. 144.68KB
MSB Trading Halt
11/05/20PRICE SENSITIVE download Created with Sketch. 170.3KB
MSB First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS
06/05/20 download Created with Sketch. 128.22KB
MSB Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
30/04/20PRICE SENSITIVE download Created with Sketch. 140.07KB
MSB Appendix 4C - quarterly
29/04/20PRICE SENSITIVE download Created with Sketch. 193.38KB
MSB 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
24/04/20PRICE SENSITIVE download Created with Sketch. 144.87KB
MSB Inflammatory Lung Disease Outcomes For Presentation at ISCT
17/04/20 download Created with Sketch. 116.14KB
MSB US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
09/04/20PRICE SENSITIVE download Created with Sketch. 95.91KB
MSB FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
06/04/20PRICE SENSITIVE download Created with Sketch. 89.95KB
MSB FDA Accepts BLA for RYONCIL and Agrees to Priority Review
01/04/20PRICE SENSITIVE download Created with Sketch. 92.3KB
MSB Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
30/03/20 download Created with Sketch. 94.18KB
MSB Change of Director's Interest Notice
20/03/20 download Created with Sketch. 71.77KB
MSB Appendix 2A
17/03/20 download Created with Sketch. 147.18KB
MSB Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
10/03/20PRICE SENSITIVE download Created with Sketch. 98.41KB
MSB Mesoblast Provides Half Year Results and Corporate Update
27/02/20PRICE SENSITIVE download Created with Sketch. 223.76KB
MSB Half Year Financial Results Presentation
27/02/20 download Created with Sketch. 1.46MB
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/20PRICE SENSITIVE download Created with Sketch. 757.72KB
MSB Mesoblast Half Year FY 2020 Financial Results Analyst Call
25/02/20 download Created with Sketch. 70.25KB
MSB Ryoncil Results in Children with Acute GvHD Presented at TCT
24/02/20 download Created with Sketch. 146.94KB
MSB Appendix 3G
21/02/20 download Created with Sketch. 131.61KB
MSB Positive Outcomes Using Remestemcel-L in Chronic GVHD
20/02/20 download Created with Sketch. 94.61KB
MSB Appendix 2A
07/02/20 download Created with Sketch. 165.97KB
MSB Mesoblast Submits Completed BLA for Ryoncil to US FDA
03/02/20PRICE SENSITIVE download Created with Sketch. 114.77KB
MSB Appendix 4C - quarterly
29/01/20PRICE SENSITIVE download Created with Sketch. 219.65KB
MSB Appendix 2A
24/01/20 download Created with Sketch. 147.69KB
MSB Biotech Showcase Presentation
15/01/20 download Created with Sketch. 2.05MB
MSB MSB Presents Commercial Plans at 2020 Biotech Showcase
15/01/20 download Created with Sketch. 144.16KB
MSB Appendix 2A
02/01/20 download Created with Sketch. 143.67KB
MSB MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
02/01/20PRICE SENSITIVE download Created with Sketch. 128.07KB
MSB DMC Completes Final Review of Phase 3 Heart Failure Trial
18/12/19PRICE SENSITIVE download Created with Sketch. 119.18KB
MSB CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
17/12/19PRICE SENSITIVE download Created with Sketch. 122.93KB
MSB CHF P3 Trial Accrues Sufficient Primary Endpoint Events
17/12/19PRICE SENSITIVE download Created with Sketch. 122.57KB
MSB Ceasing to be a substantial holder
05/12/19 download Created with Sketch. 212.21KB
MSB Change of Director's Interest Notice
05/12/19 download Created with Sketch. 70.89KB
MSB Results of Meeting
27/11/19 download Created with Sketch. 183.19KB
MSB Mesoblast Chairman Message to 2019 AGM
27/11/19 download Created with Sketch. 105.21KB
MSB Presentation to 2019 Annual General Meeting
27/11/19 download Created with Sketch. 1.64MB
MSB MSB Provides Q1 Financial Results and Operational Highlights
26/11/19PRICE SENSITIVE download Created with Sketch. 309.78KB
MSB First Quarter Results Presentation
26/11/19 download Created with Sketch. 1.67MB
MSB First Quarter Financial Results on Form 6-K
26/11/19PRICE SENSITIVE download Created with Sketch. 502.82KB
MSB Appendix 4C - quarterly
31/10/19PRICE SENSITIVE download Created with Sketch. 212.78KB
MSB Annual Report to shareholders
29/10/19 download Created with Sketch. 5.08MB
MSB Notice of General Meeting/Proxy Form
29/10/19 download Created with Sketch. 304.7KB
MSB Appendix 4G and Corporate Governance Statement
29/10/19 download Created with Sketch. 242KB
MSB Appointment of Joint Company Secretary
29/10/19 download Created with Sketch. 92.31KB
MSB Ceasing to be a substantial holder
23/10/19 download Created with Sketch. 41.85KB
MSB Change in substantial holding
23/10/19 download Created with Sketch. 85.89KB
MSB Change in substantial holding
23/10/19 download Created with Sketch. 231.98KB
MSB MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
17/10/19PRICE SENSITIVE download Created with Sketch. 94.01KB
MSB Change in substantial holding
10/10/19 download Created with Sketch. 526.49KB
MSB Cleansing notice and Appendix 3B
08/10/19 download Created with Sketch. 197.29KB
MSB Change in substantial holding
08/10/19 download Created with Sketch. 71.35KB
MSB Mesoblast Raises A$75 Million
03/10/19PRICE SENSITIVE download Created with Sketch. 112.24KB
MSB Trading Halt
01/10/19PRICE SENSITIVE download Created with Sketch. 288.32KB
MSB Release of Shares from Voluntary Escrow
27/09/19 download Created with Sketch. 86.42KB
MSB Mesoblast Newsletter - Chronic Low Back Pain
27/09/19 download Created with Sketch. 575.08KB
MSB Analyst Call Presentation
10/09/19 download Created with Sketch. 1.7MB
MSB Analyst Call Details
10/09/19 download Created with Sketch. 83.18KB
MSB Grunenthal and MSB Enter Strategic Partnership for Back Pain
10/09/19PRICE SENSITIVE download Created with Sketch. 127.73KB
MSB Mesoblast Reports on Annual Results
30/08/19PRICE SENSITIVE download Created with Sketch. 243.33KB
MSB Annual Financial Results Presentation
30/08/19 download Created with Sketch. 4.48MB
MSB Preliminary Final Report including Appendix 4E
30/08/19PRICE SENSITIVE download Created with Sketch. 3.68MB
MSB FDA Guidance on Clinical Pathway for LVAD Market Application
27/08/19PRICE SENSITIVE download Created with Sketch. 108.18KB
MSB Investigator-Initiated Trial Planned for Chronic GVHD
14/08/19 download Created with Sketch. 73.45KB
MSB Mesoblast Appoints Leading Pharma Industry Executive as CMO
12/08/19 download Created with Sketch. 72.69KB
MSB Appendix 4C - Quarterly, Strong Commercialization Revenues
31/07/19PRICE SENSITIVE download Created with Sketch. 198.68KB
MSB Circulation Research Highlights MSB Heart Failure Therapy
25/07/19PRICE SENSITIVE download Created with Sketch. 125.8KB
MSB Newsletter - Interview with GvHD Key Opinion Leader
15/07/19 download Created with Sketch. 931.81KB
MSB Change in substantial holding
12/07/19 download Created with Sketch. 77.12KB
MSB Appendix 3B
11/07/19 download Created with Sketch. 113.03KB
MSB Release of Shares from Voluntary Escrow
26/06/19 download Created with Sketch. 86.12KB
MSB FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
24/06/19PRICE SENSITIVE download Created with Sketch. 134.93KB
MSB High Economic Burden In Steroid-Refractory aGVHD
18/06/19 download Created with Sketch. 94.6KB
MSB MSB to Host Virtual Symposium with KOL on GvHD
17/06/19 download Created with Sketch. 92.26KB
MSB MSB Expands JCR Partnership To Brain Disease In Newborns
11/06/19PRICE SENSITIVE download Created with Sketch. 94.26KB
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/19PRICE SENSITIVE download Created with Sketch. 184.53KB
MSB Third Quarter Results Presentation
31/05/19 download Created with Sketch. 3.41MB
(20min delay)
Last
$4.40
Change
0.100(2.33%)
Mkt cap ! $2.571B
Open High Low Value Volume
$4.27 $4.48 $4.23 $31.89M 7.270M

Buyers (Bids)

No. Vol. Price($)
11 40300 $4.40
 

Sellers (Offers)

Price($) Vol. No.
$4.42 16656 2
View Market Depth
Last trade - 16.10pm 07/08/2020 (20 minute delay) ?
(live)
Last
$4.43
  Change
0.100 ( 3.17 %)
Open High Low Volume
$4.28 $4.47 $4.24 1560205
Last updated 15.59pm 07/08/2020 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.